BioXcel Therapeutics Inc. (BTAI) Financial Ratios & Valuation Metrics Analysis - P/E, ROE, Debt Ratios & Profitability - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    BioXcel Therapeutics Inc.

    NASDAQ: BTAI · Real-Time Price · USD
    3.79
    0.22 (6.16%)
    At close: Sep 05, 2025, 3:59 PM
    3.88
    2.37%
    After-hours: Sep 05, 2025, 07:55 PM EDT

    BioXcel Therapeutics Ratios and Metrics

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    PE Ratio
    		 -0.25 -7.68 -58.09 -80.45
    PEG Ratio
    		 -0.00 -23.54 -1.12 -11.7
    PS Ratio
    		 6.69 996.30 25.68K n/a
    PB Ratio
    		 -0.16 -24.33 125.41 38.70
    P/FCF Ratio
    		 -0.21 -8.87 -71.07 -103.86
    P/OCF Ratio
    		 -0.21 -8.87 -71.14 -104.42
    OCF/S Ratio
    		 -31.79 -112.32 -360.91 n/a
    Debt / Equity Ratio
    		 -1.11 -1.79 1.23 0.01
    Quick Ratio
    		 1.65 2.57 6.11 14.21
    Current Ratio
    		 1.68 2.65 6.17 14.21
    Asset Turnover
    		 0.06 0.02 0.00 n/a
    Interest Coverage
    		 -4.44 -12.9 -19.44 -2.67K
    Return on Equity
    		 0.64 3.17 -2.16 -0.48
    Return on Assets
    		 -1.55 -2.43 -0.81 -0.45
    Return on Invested Capital
    		 -3.99 -3.65 -0.92 -0.47
    Dividend Yield
    		 n/a n/a n/a n/a
    Payout Ratio
    		 n/a n/a n/a n/a
    Gross Profit Margin
    		 0.05 0.09 0.95 n/a
    Net Profit Margin
    		 -26.3 -129.75 -442.02 n/a
    Pretax Profit Margin
    		 -26.3 -129.75 -442.02 n/a
    Operating Profit Margin
    		 -29.68 -124.48 -425.72 n/a
    FCF Margin
    		 -31.79 -112.34 -361.28 n/a
    EBITDA Margin
    		 -19.49 -119.87 -419.69 n/a

    Add to Watchlist